A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Status:
Recruiting
Trial end date:
2025-04-21
Target enrollment:
Participant gender:
Summary
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with
lymphoma or chronic leukemia who have already had standard of care treatment. Participation
could last up to four years.